to determine the fetal sex. It is well known that the fetal fraction, i.e., the cffDNA subfraction from the total maternal and fetal cfDNA in the plasma, correlates with test success and interpretation reliability (1 ) . The cffDNA represents on average 6%-10% of the total cfDNA in first-and second-trimester pregnancies, and increases to 10%-20% in third-trimester pregnancies (2, 3 ) . However, the fetal fraction can remain Ͻ4% in the first trimester (4, 5 ) . To conclude whether a negative result of an NIPD assay is a true or false negative, a marker to confirm the presence of fetal nucleic acids (a fetal marker) is crucial. The ideal fetal marker can be used as an internal control in the same test to detect any technical failure of the assay. As such, the fetal marker should be (a) part of the NIPD assay, (b) specific for fetoplacentally derived nucleic acids, and (c) sex-independent.
Trophoblastic cells from the fetal part of the placenta are the source of cffDNA (6 ) . cfRNA derived from genes that are expressed only by the trophoblastic cells may be used as a sex-independent marker to prove the presence of fetoplacentally derived nucleic acids in the plasma sample. Trophoblast-derived messenger RNA (mRNA) of the pregnancy-specific hormones placental lactogen (PL) and human chorionic gonadotropin (hCG) is constantly released into maternal plasma during pregnancy (7, 8 ) . The amount of cfRNA in maternal plasma corresponds with known expression patterns of the genes in the villous layer during placental development and with concentrations of released hormone in maternal serum (7, 9, 10 ) . Therefore, the amount of hCG cfRNA is highest in the first trimester of pregnancy, whereas the amount of PL cfRNA is highest in the third trimester (7, 8 ) . This cfRNA is stable and rapidly cleared after delivery (7 ) . cfRNA has been used as a marker to detect placental disease, fetal hypoxia, or ectopic pregnancy, but not as a fetal marker in noninvasive genetic tests (11) (12) (13) (14) .
This study examines the use of trophoblast-derived cfRNA as a fetoplacental marker in noninvasive fetal sex determination. Noninvasive fetal sex determination is often requested in case of a fetus at risk for 1 of the Ͼ100 known X-linked inherited disorders or for autosomal recessive congenital adrenal hyperplasia (15, 16 ) . Furthermore, if a fetus presents with ambiguous genitalia on ultrasound examination, prenatal determination of the genetic sex can be part of the structured approach to detect the underlying condition. In the case of amplification of Y chromosomederived cffDNA sequences in maternal plasma by realtime quantitative PCR (qPCR) or standard PCR, the fetus is presumed to be male. If no Y chromosomederived cffDNA sequences are amplified, the fetus is most likely female, but this could also be the result of an insufficient amount of cffDNA. To date, in general, 2 methods are used to confirm that cffDNA is present in the sample. The first is the detection of paternally inherited alleles (17 ) , and the second is the amplification of hypermethylated placental genes, such as RASSF1A [Ras association (RalGDS/AF-6) domain family member 1, isoform A], 5 after removing maternal unmethylated gene sequences by a methylationsensitive endonuclease (18 ) . Both approaches have drawbacks. They require extra time and expense by the laboratory, and they sometimes fail to confirm the presence of fetal nucleic acids (17, 18 ) . In addition, the first method requires paternal DNA. As a consequence, the ideal fetal marker for noninvasive sex determination, which is incorporated in the test and requires no extra time or expense, is not yet available. In this study, we developed a novel single-tube NIPD assay for fetal sex determination by combining amplification of AMELY (amelogenin, Y-linked) cffDNA with one-step reverse transcription (RT)-PCR of trophoblast-derived cfRNA, which functions as a sexindependent fetoplacental marker. We present a proof-of-principle study in 75 pregnant women with known pregnancy outcomes.
Materials and Methods

BLOOD SAMPLE COLLECTION
We collected EDTA-anticoagulated blood samples of 75 pregnant women at 9 ϩ 4 to 34 ϩ 1 weeks (ϩ days) of gestation at the Department of Clinical Genetics of the Maastricht University Medical Center, the Netherlands. These pregnant women were scheduled to undergo invasive chorionic villous sampling or amniocentesis for prenatal microarray analysis because of structural abnormalities seen on prenatal ultrasound scan. Parental blood samples were collected for interpretation studies should an abnormality be detected in the prenatal sample upon array analysis. Additionally, we used EDTAanticoagulated blood samples from 20 randomly selected male partners as positive Y chromosome control samples and from 20 nonpregnant women of reproductive age (nulli-, primi-, and multipara women) as negative nonpregnant non-Y chromosome control samples. Blood was stored at 4°C before processing. All participants agreed to the use of their coded body material for improvement of diagnostic tests, according to the Code of Conduct for Responsible Use of Human Tissue and Medical Research in the Netherlands. The sample characteristics are listed in Table 1 . Further laboratory tests were conducted blinded to the clinical characteristics of the samples, except for the gestational age of the women at the time of blood sample collection.
The blood samples of the controls were anonymized. Only the parity and number of male offspring were registered from the nonpregnant females. The women had 0 -2 male pregnancies in the past.
SAMPLE PROCESSING AND cfDNA/RNA EXTRACTION Fig. 1 illustrates the test procedure and the suggested time schedule. The blood samples were centrifuged at 1600g for 10 min at 4°C. The plasma portion was transferred into plain polypropylene tubes and centrifuged at 7470g for 10 min at 4°C. Cryogenic vials containing the supernatant were stored at Ϫ80°C until cfDNA/RNA extraction.
We performed simultaneous extraction of total cfDNA and cfRNA in duplicate from 2ϫ 2 mL plasma from the pregnant women with the QIAamp Circulating Nucleic Acid Kit (Qiagen), following a slightly adjusted protocol (see Supplemental Data, which accompanies the online version of this article at http://www.clinchem.org/ content/vol61/issue12). The cfDNA/RNA (elution volume 50 L) was subsequently stored at Ϫ80°C for optimal conservation of the cell-free nucleic acids. Additionally, we performed 1 cfDNA/RNA extraction with 1 mL plasma from the nonpregnant females and male controls (elution volume 25 L).
PRIMER DESIGN
To investigate the presence of trophoblast-derived cfRNA in the maternal plasma, we designed oligonucleotide primer pairs for specific RT and amplification of trophoblast-expressed genes encoding the hormones PL and hCG. For PL, these are the highly similar genes CSH1 and CSH2 [respectively, chorionic somatomammotropin hormone 1 (placental lactogen) and chorionic somatomammotropin hormone 2], and for hCG, 4 highly homologous genes: CGB (chorionic gonadotropin, ␤ polypeptide), CGB5, CGB7, and CGB8 [chorionic gonadotropin, ␤ polypeptides 5, 7, and 8, respectively] (10, 19 ) .
The primers were developed with the free web program Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/ primer3). Criteria for primer design were primer size (20 -30 nucleotides), GC content (40%-60%), melting temperature of the primers (65°C-70°C, optimal 68°C), primers preferably ending 3Ј with a guanine or cytosine, and RNA PCR product lengths between 60 and 150 bp. The primers anneal to sequences in exons on both sides of an intron. As a result, a larger product amplified from cfDNA (both maternal and fetoplacental) and a smaller product amplified from the intronless cfRNA (fetoplacental) is predicted. The cfDNA product will provide an internal control in cases in which no amplification of cfRNA is expected, e.g., in plasma samples from males and nonpregnant females. All forward primers were fluorophore-labeled, allowing visualization of the PCR products after separation by a capillary sequencer. The sequences of the primers, their fluorescent labels, and the theoretic cfDNA and cfRNA product sizes are listed in Table 2 .
Because of the Ͼ85%-90% sequence identity among the genes in the human growth hormone/CSH gene cluster (17q22-24) and the LHB (luteinizing hormone ␤ polypeptide)/CGB gene cluster (19q13.3), our primers will most likely also initiate RT and amplification of cfRNA from other trophoblast-expressed genes. These are CSHL1 (chorionic somatomammotropin hormone-like 1), a paralog gene of CSH1 and CSH2, and CGB1 and CGB2 (chorionic gonadotropin, ␤ polypep- tides 1 and 2, respectively). The function of these genes is currently unclear, but their expression is trophoblast specific (9, 10, 20 ) . We expect amplification products of the same size in all genes and transcript variants of the genes (see online Supplemental Fig. 1 ). As such, the combined amplification of the cDNA of all genes can be used to investigate the presence of trophoblast-derived cfDNA. We refer to the amplified genes in the human growth hormone/CSH gene cluster as "CSH genes" and those in the LHB/CGB gene cluster as "CGB genes" throughout this article.
To detect Y chromosome-specific cffDNA in the maternal plasma, we designed oligonucleotide primer pairs for the amplification of AMELY (Yp11.2). To facilitate combination of all primer pairs in a multiplex test, the primers were developed with Primer3 and the same criteria for primer design as for the cfRNA targets. The primers were designed to overlap with mismatches compared with the homologous gene on the X chromosome: AMELX (amelogenin, X-linked) (Xp22.31-p22.1). As a result, amplification of maternal cfDNA derived from the X chromosome was avoided (see online Supplemental 2.1 L PCR primer mix (containing 10 pmol CGB forward and reverse primer, 7 pmol CSH forward and reverse primer, and 8 or 4 pmol AMELY forward and reverse primer, for gestational ages Ͻ15 weeks and Ͼ15 weeks, respectively).
RT-PCR was performed on the GeneAmp ® PCR System 9700 (Applied Biosystems). The reaction was initiated at 50°C for 30 min, allowing specific RT of CSH and CGB genes cfRNA. This was followed by 95°C for 15 min for inactivation of the reverse transcriptases, denaturation of the cDNA and cffDNA template, and activation of the HotStarTaq DNA polymerase. Simultaneous amplification of AMELY cffDNA and CSH and CGB genes cDNA was conducted by 10 cycles of 94°C for 10 s, 66°C for 1 min, and 72°C for 1 min, followed by 35 cycles of 94°C for 10 s, 66°C for 30 s, and 72°C for 30 s. The reaction was ended by a final incubation at 72°C for 10 min. The RT-PCR products were either immediately separated and analyzed or stored at Ϫ20°C.
SEPARATION OF RT-PCR PRODUCTS AND DATA ANALYSIS
The fluorescently labeled RT-PCR products were diluted 1:100 (1 part RT-PCR product and 99 parts H 2 O) before separation and separated by capillary electrophoresis on the ABI 3730 DNA Analyzer (Applied Biosystems by Life Technologies). The sizes, peak heights, and areas under the amplification peaks of the RT-PCR products were analyzed with data analysis software (GeneMarker v2.4.0, Soft Genetics).
Results
ANALYSIS OF THE ELECTROPHEROGRAMS
The nonspecific background for each of the cfRNA and cfDNA amplification products was determined by use of the 40 plasma samples from the nonpregnant female and male controls. For all subsequent analyses, we used the criterion that if the area under the amplification peak was above the nonspecific background, a peak was considered present. Fig. 2 shows the primer binding sites in the exons, the theoretic sizes of the cfDNA and cfRNA products, and examples of the amplified fluorescent RT-PCR products in different sample types. The electropherogram of all sample types (pregnant and nonpregnant controls) showed 2 amplified VIC fluorescent dye-labeled products of 160 and 361 bp, representing CSH and CGB genes cfDNA, respectively. In case of a pregnancy, 2 smaller VIC-labeled products were seen (64 and 125 bp), representing CSH and CGB genes cfRNA, respectively. In case of the presence of a Y chromosome (male fetus or adult male), the electropherograms showed an amplified NED dye-labeled product of 76 bp representing AMELY cffDNA or cfDNA. No trophoblast-derived cfRNA peaks were found in the 40 control plasma samples in which no fetoplacental nucleic acids were expected (20 males and 20 nonpregnant females).
FETOPLACENTAL MARKERS THROUGHOUT PREGNANCY
The fetoplacental marker was considered present if the trophoblast-derived cfRNA peaks were detected according to gestational age, i.e., according to the expression patterns during placental development. In the first trimester of pregnancy, we expected the area under the CGB genes cfRNA amplification peak to be higher than that of the CSH genes cfRNA amplification peak. In the second and third trimesters of pregnancy, we expected the area under the CGB genes cfRNA amplification peak to be below the area of the CSH genes cfRNA amplification peak. To confirm this, we evaluated the cfRNA peaks in the 75 plasma samples from the pregnant women. The ratio of both areas (CSH to CGB peak ratio) was calculated for each sample. The distribution of the CSH to CGB peak ratio throughout pregnancy is shown in Fig. 3 . Indeed, from this graph it can be seen that all firsttrimester samples had a higher area under the CGB genes cfRNA amplification peak than under the CSH genes cfRNA amplification peak, and that with increasing gestational age the CSH to CGB peak ratio increases. Electropherograms early and later in the pregnancy illustrate this trend in online Supplemental Fig. 3 .
DETERMINATION OF FETAL SEX
The sample was considered to be derived from a woman carrying a male fetus in the case of a positive result for AMELY cffDNA and trophoblast-derived cfRNA amplification in both RT-PCRs. The fetus was considered to be female in the case of a negative AMELY cffDNA amplification result and a positive trophoblast-derived cfRNA amplification result in both RT-PCRs.
The AMELY and cfRNA amplification result was unambiguous and identical after conducting the duplicate one-step RT-PCR once in 71 of 75 plasma samples (Fig. 4) . In 41, a distinct positive result for the AMELY cffDNA and cfRNA amplification was seen in both RTPCRs, whereas the remaining 30 samples showed no AMELY cffDNA amplification in combination with a positive cfRNA result in both RT-PCRs. We classified the first 41 samples as male fetuses and the latter 30 samples as female fetuses.
Three samples required a third replicate of RT-PCR (NY-19, 15 ϩ 1 weeks; NY-41, 14 ϩ 1 weeks; NY-49, 21 ϩ 1 weeks). They were classified as "probably female" fetuses after the second test, because the presence of fetoplacentally derived nucleic acids was evident in only 1 of the 2 RT-PCRs. We repeated the dubious RT-PCR run in all 3 samples with the same starting materials and conditions. Thereafter, a 100% concordance rate between the clear RT-PCR and the repeated RT-PCR was reached for all samples. Samples NY-19, NY-41, and (A), Primer binding sites in the exons. GeneMapper electropherograms showing the amplified fluorescent products in a plasma sample of a woman carrying a male fetus (9 + 4 weeks of gestation) (B); a woman carrying a female fetus (19 + 4 weeks of gestation) (C); an adult nonpregnant woman (D); and an adult male (E). In all samples, 2 VIC-labeled products of 160 and 361 bp, representing CSH and CGB genes cfDNA, respectively, were detected (A-E). In case of a pregnancy, 2 smaller VIC-labeled products were seen (64 and 125 bp), representing CSH and CGB genes cfRNA, respectively (A-C). In case of a male fetus or adult male, an amplified NED-labeled product of 76 bp representing AMELY cffDNA or cfDNA was detected (A, B, E).
NY-49 were thus all classified as female-bearing pregnancies. A last sample required a rerun of the duplicate RT-PCR. No sex could be determined for the sample (NY-36, 19 ϩ 6 weeks), because no AMELY cffDNA amplification and no positive cfRNA result was found in either RT-PCR. The same starting materials and conditions were used during the rerun. In both cfDNA/RNA isolations, the fetoplacental marker was present, as well as an AMELY cffDNA peak. Apparently, both RT-PCRs had initially failed, although they were performed at separate times. This sample was now classified as being derived from a woman carrying a male fetus.
Comparison of the result of our noninvasive fetal sex determination test with the result of invasive prenatal testing and pregnancy outcomes revealed that the fetal sex was correctly determined in all of these 75 samples (100%).
Discussion
This study examined the use of cfRNA as a fetoplacental marker incorporated in a noninvasive fetal sex determination assay. In our proof-of-principle study, 75 blinded plasma samples from pregnant women were tested to find out whether the fetal sex could be determined and whether cfRNA was a reliable fetoplacental marker in this process.
The fetal sex could be determined unequivocally after conducting RT-PCR once in 2 separate cfDNA/RNA isolations in the majority of the plasma samples (95%). Absence of the fetoplacental marker in 1 of both RTPCRs in 5% of the cases required a repeat RT-PCR to have an unambiguous result for fetal sex determination.
After these replicates, the fetoplacental markers turned out to be present in all samples. More importantly, the fetal sex was correctly determined in all cases (100%).
Because of low template DNA, a noninvasive fetal sex determination assay sometimes requires multiple replicates to provide an unambiguous indication of fetal sex (17, 18 ) . In clinical practice, it is advisable to test each cfDNA/RNA extraction at least twice. If the fetoplacental marker is not detected after repeated testing in AMELY-negative samples, it is recommended to redraw blood from the pregnant women.
Our proof-of-principle study results indicate that the presence of the fetoplacental cfRNA marker in this single-tube assay is tightly correlated with an adequate amount of cffDNA in the plasma for noninvasive sex determination. We conclude this on the basis that in all pregnancies with male fetuses, both AMELY cffDNA and trophoblast-specific cfRNA were reliably detected, and in none was AMELY cffDNA detected without the trophoblast-specific cfRNA peaks. Also, in none of these samples were the trophoblast-specific cfRNA peaks present while the AMELY cffDNA peak was absent. Moreover, we would have determined 1 sample from a male fetus as being derived from a female-bearing pregnancy without the use of the fetoplacental marker. In addition, no AMELY cffDNA was detected above background in any of the nullipara or multipara nonpregnant women or women carrying a female fetus. In case of a negative result of the cffRNA marker, however, it was also clear there was an insufficient amount of fetal nucleic acids present (if not due Box plots represent the distribution of CSH to CGB peak ratio in the first, second, and third trimesters in the sample set of 75 pregnant women.
cffDNA and cfRNA for Noninvasive Fetal Sex Determination to a technical failure) and the test needed to be repeated, on the same or a new blood sample.
Clearly, this proof-of-principle study needs further replication before entering the diagnostic arena. One of the limitations of our study is that we did not test samples from pregnant women at 7-8 weeks of gestation and only 1 at 9 weeks of gestation (male fetus). However, our data do not show a decreased detection rate for 8 pregnancies at 11 weeks of gestation. After conducting the duplicate one-step RT-PCR once, the fetal sex was unambiguous and correct in all 8 samples (2 male fetuses, 6 female fetuses). Although these numbers are small, they suggest that the assay can be reliably applied early in pregnancy. A follow-up study, including samples from women between 7 and 10 weeks of pregnancy, is now recommended.
RT of cfRNA to cDNA could be added to other noninvasive prenatal tests investigating fetal alleles, e.g., for monogenic traits. cfDNA and cfRNA are extracted simultaneously from the plasma sample in most extraction kits, and therefore no additional procedure is necessary to obtain cfRNA. The cfRNA peaks did not appear to be strongly influenced by high BMI or longer storage of blood, plasma, or cfDNA/ RNA. As an example, the cfDNA/RNA of NY-92 was stored for 11 months at Ϫ80°C before analysis. This was a plasma sample collected at 13 ϩ 2 weeks of gestation from a woman with a BMI of 30.9. The cfRNA peak areas obtained for this sample are in the expected range for gestational age. This was also found in the other samples stored for a long time and in all women with high BMI. The fetal sex could be determined unequivocally after conducting the RT-PCR once in 2 separate cfDNA/RNA isolations in 71 of 75 plasma samples. Three samples required a third repeat, and 1 sample required a rerun of the duplicate RT-PCR for a definitive conclusion, because of an absent fetoplacental marker. Thereafter, fetal sex was correctly determined in all 75 plasma samples.
Our test is based on AMELY only for fetal sex determination. Sex determination on the basis of AMELY is widely accepted in genetic diagnosis for sex determination, e.g., in the forensic field, prenatal diagnosis, and preimplantation genetic diagnosis. However, a few cases with AMELY deletion resulting in allelic dropout have been reported in different populations (21 ) . The frequency of AMELY negatives is low, and ethnic differences seem to exist (0.018% in Europe, 0.02% in Australia, 1.85%-2.36% in India) (21, 22 ) . In a pilot study, we have attempted to incorporate other Y chromosome genes, SRY (sex-determining region Y) and UTY (ubiquitously transcribed tetratricopeptide repeat containing, Y-linked), but found too many primer interactions in the multiplex RT-PCR (data not shown).
Finally, massively parallel sequencing approaches also can be used to determine the sex of the fetus, but at the moment this is still rather expensive (23, 24 ) . Our noninvasive fetal sex determination assay is a useful addition to the next-generation sequencing flow, as it is cheap, fast, and easy to use and provides a result within 1 or 2 days. Furthermore, it can be conducted in laboratories that do not have access to next-generation sequencing facilities.
In conclusion, in this proof-of-principle study, we have shown that amplification of placenta-expressed genes is an elegant way to confirm the presence of fetal nucleic acids in the maternal plasma and can be combined in a single tube with a sex-determination assay. 
